About the Safety Working Group
Harms provide important context for healthcare practitioners about the benefit-risk ratio of interventions. To improve transparency and credibility in the published results from randomized trials, the reporting of harms associated with an intervention needs to be explicit regarding what is patient-important, which may be different from that reported by clinicians submitting adverse event reports
Following the concerns about inadequate reporting of harm outcomes in randomized trials and systematic reviews the Outcome Measures in Rheumatology (OMERACT) Safety Working Group is advancing the work to identify additional harm aspects for assessment in rheumatology trials
![Peter Brooks Peter Brooks](https://omeract.org/wp-content/uploads/bb-plugin/cache/Peter-Brooks-circle-d40d7df45c04a457ddb7489f28cf028c-.jpeg)
Peter Brooks
Co-Chair
![Robin Christensen Robin Christensen](https://omeract.org/wp-content/uploads/bb-plugin/cache/Robin-Christensen-circle-d79d0a64dd8ce36db49508b8842b5dc6-.png)
Robin Christensen
Co-Chair
![Caroline Flurey Caroline Flurey](https://omeract.org/wp-content/uploads/bb-plugin/cache/Caroline-Flurey-circle-7d9ff202e9357693cf4f4b123ac639fb-.png)
Caroline Flurey
Co-Chair
![Lee Simon Lee Simon](https://omeract.org/wp-content/uploads/bb-plugin/cache/Lee-Simon-scaled-circle-36c072cd5c20d2b5bf4df8e86609d3ae-.jpg)
Lee Simon
Co-Chair
![dorthe dorthe](https://omeract.org/wp-content/uploads/bb-plugin/cache/dorthe-scaled-circle-c15527421dc027f33d79bbde8a42dcc0-.jpg)
Dorthe Bang Berthelsen
Fellow
![Pam Richards Pam Richards](https://omeract.org/wp-content/uploads/bb-plugin/cache/Pam-Richards-circle-f685a20b70ab2c6d870c39837efa86c0-.png)
Pam Richards
Patient Research Partner
![Marieke Scholte-Voshaar Marieke Scholte-Voshaar](https://omeract.org/wp-content/uploads/bb-plugin/cache/Marieke-Scholte-Voshaar-circle-8800c3954012ff8b20a78d95529e0649-.png)
Marieke Voshaar
Patient Research Partner
How patients can help the Safety Working Group to improve reporting of side effects from rheumatological medications.
Working Group Publications
Harms reported by patients in rheumatology drug trials: a systematic review of randomized trials in the cochrane library from an OMERACT working group
Improving benefit-harm assessment of therapies from the patient perspectives: OMERACT pre-meeting towards consensus on core sets for randomized controlled trials
Patient Perspectives on DMARD Safety Concerns in Rheumatology Trials: Results from Inflammatory Arthritis Patient Focus Groups and OMERACT Attendee Discussions
Identifying Possible Outcome Domains from Existing Outcome Measures to Inform an OMERACT Core Domain Set for Safety in Rheumatology Trials
Developing an OMERACT Core Outcome Set for Assessing Safety Components in Rheumatology Trials: The OMERACT Safety Working Group
Working Group Members:
Alessandro Giollo
Amanda Burls
Amye Leong
Andrea Falzon
Anupam Wakhlu
Aya Akmal Amin
Ayano Kelly
Bev Shea
Birthe Mette Pedersen
Caroline Flurey
Catherine Hill
Charmaine Jones
Chris Djurtoft
Clifton (Bing) Bingham
Daniel Devoe
Daniel Furst
Dario Scublinsky
Deb Constien
Denise Bury-Maynard
Dorcas Beaton
Dorthe Bang Berthelsen
Edward Henstridge
Elisabeth Ginnerup Læbo
Emily Schildt
Gabriela Tabaj
Glen Hazelwood
Ilfita Sahbudin
Inna Gaydukova
Jane Hayes
Jasvinder Singh
Javier Rios
Jorge Juan Fragío Gil
Karina Torralba
Laura Dayries
Laura Sergison
Lee Simon
Lyn March
Lynne Matallana
Maarten Boers
Maarten de Wit
Maria Suarez-Almazor
Marieke Voshaar
Marianne U. Rasmussen
Marios Kouloumas
Marita Cross
Maxine Isbel
Nino Tsiskarishvili
Niti Goel
Oliver Kraemer
Orit Schieir
Pam Richards
Patricia Hurley
Patrick Durez
Paula Williamson
Peter Brooks
Peter Tugwell
Phyllis Bass
Randall Stevens
Rebecca Sweet
Robin Christensen
Sabrina M Nielsen
Samar Tharwat Radwan
Stacey Grealis
Susan Bartlett
Susan Goodman
Tamer Gheita
Tanja Schjødt Jørgensen
Thasia Woodworth
Torkell Ellingsen
Vibeke Strand
Yeonhew Kim